New measures to minimise animal testing to be implemented in Europe
The European Medicines Agency is promoting three principles – replace, reduce and refine – to reduce animal testing in medicine development.
List view / Grid view
The European Medicines Agency is promoting three principles – replace, reduce and refine – to reduce animal testing in medicine development.
Save time by measuring 48 immune factors, generating more than 1,800 data points from a single plate, with a small sample volume.
A CRISPR screening tool identified a new target for acute myeloid leukaemia with fewer side effects than current approaches.
Scientists have discovered that approved antidepressant drugs cause immune cells to recognise and eliminate tumour cells in mouse models.
Sinopia has been awarded a $3.3 million Fast-Track SBIR grant to fund the study for its small molecule candidate for Parkinson’s disease.
Stealth BioTherapeutics reported positive data from a pre-clinical study evaluating SBT-272 in a murine model of Parkinson's disease.
Limiting neuroinflammation was shown to be a promising approach to treat neurological diseases such as stroke and spinal cord injury in mice.
The over-expression of a growth factor receptor resulted in hypomyelination, leading to diseases such as multiple sclerosis in mouse models.
Elicio Therapeutics’ lymph node-targeting vaccine displayed cellular and humoral immunity to SARS-CoV-2 in a pre-clinical study.
Despite the rapid deployment of vaccines among global populations, therapeutics such as antibodies are still required. Here, Dr Steve Carroll, Vice President of Pre-clinical Sciences at IGM Biosciences, explains how a potential Immunoglobulin M (IgM) antibody treatment has been developed that shows promise for combatting SARS-CoV-2 and variants of concern in pre‑clinical…
Scientists have used exosomes to deliver a novel protein that prevented HIV from replicating in the bone marrow, spleen and brain of mouse models.
Guided by precise biomarker tests, therapeutic vaccines targeting the pathology of neurodegenerative disease could provide solutions to the impending global crisis in dementia. As Dr Andrea Pfeifer, Co-Founder, Chief Executive Officer and Director of AC Immune, describes here, current work is both establishing the targets that those vaccines must address…
Two different peptides were found to slow the spread of alpha-synuclein, potentially becoming the first drugs to slow the progression of Parkinson’s disease.
Interleukin 13 receptor alpha 2 was found in increased rates in cancer cells that metastasised to the brain and lungs, a new study has shown.
New research has revealed that club cells secret anti-immunosuppressive factors in tumours, potentially revolutionising cancer therapies.